The COVID-19 pandemic is primarily caused by the SARS-CoV-2 or coronavirus with a significant higher morbidity and mortality all around the globe. More than 3.78 million individuals have been killed, leaving almost no region untouched worldwide. The SARS-CoV-2 is a positive sense ssRNA, a zoonotic origin virus which commonly habitats in horseshoe bats. Since, the advent of this pandemic, the major agencies worldwide has started research for developing therapeutics and medicine against this disease. Many medicines have been repurposed for its effective treatment. However, clinical trials for many more drugs are on the way. In this review, we propose the use of RNAi technology for silencing the genome of the virus once it gets inside the cells and for its site-specific delivery. Artificial cells and a nanotechnology technique to use micelleplexes have been proposed to deliver siRNA to the susceptible cells. The site specific delivery could be achieved by harnessing the antigenic peptide of the viral spike protein. The proposed delivery system may help to elicit an immune response against the virus and provide protection tool against the COVID-19 infections.
No takes yet. Share an insight, caveat, or question.
Prakash et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: